ACTI Stock Overview
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden.
Active Biotech AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr0.93|
|52 Week High||kr1.52|
|52 Week Low||kr0.88|
|1 Month Change||-8.47%|
|3 Month Change||-24.02%|
|1 Year Change||-33.67%|
|3 Year Change||-65.81%|
|5 Year Change||-84.24%|
|Change since IPO||-97.15%|
Recent News & Updates
Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|ACTI||SE Biotechs||SE Market|
Return vs Industry: ACTI exceeded the Swedish Biotechs industry which returned -40% over the past year.
Return vs Market: ACTI underperformed the Swedish Market which returned -28.2% over the past year.
|ACTI Average Weekly Movement||8.6%|
|Biotechs Industry Average Movement||8.0%|
|Market Average Movement||6.9%|
|10% most volatile stocks in SE Market||11.7%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: ACTI is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ACTI's weekly volatility (9%) has been stable over the past year.
About the Company
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd.
Active Biotech AB (publ) Fundamentals Summary
|ACTI fundamental statistics|
Is ACTI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACTI income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 03, 2022
|Earnings per share (EPS)||-0.22|
|Net Profit Margin||0.00%|
How did ACTI perform over the long term?See historical performance and comparison